What is HC Wainwright’s Estimate for VNDA Q1 Earnings?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for Vanda Pharmaceuticals in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS and Q4 2026 earnings at $0.14 EPS.

Separately, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Performance

Vanda Pharmaceuticals stock opened at $4.55 on Wednesday. The firm’s 50-day moving average is $4.60 and its 200-day moving average is $4.83. Vanda Pharmaceuticals has a 1 year low of $3.71 and a 1 year high of $6.75. The company has a market cap of $265.31 million, a P/E ratio of -14.22 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. The business had revenue of $53.19 million during the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Verition Fund Management LLC boosted its position in Vanda Pharmaceuticals by 7.8% during the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 2,927 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Vanda Pharmaceuticals by 17.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 3,370 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Vanda Pharmaceuticals by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock worth $2,796,000 after acquiring an additional 3,473 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 4,374 shares during the period. Finally, Franklin Resources Inc. boosted its position in Vanda Pharmaceuticals by 8.8% during the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 4,449 shares during the period. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.